```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS  4  OCT 28   KOREAPAT now available on STN
 NEWS  5  NOV 30   PHAR reloaded with additional data
 NEWS  6  DEC 01   LISA now available on STN
 NEWS  7  DEC 09   12 databases to be removed from STN on December 31, 2004
 NEWS  8  DEC 15   MEDLINE update schedule for December 2004
 NEWS  9  DEC 17   ELCOM reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  10 DEC 17   COMPUAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  11 DEC 17   SOLIDSTATE reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  12 DEC 17   CERAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  13 DEC 17   THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS  14 DEC 30   EPFULL: New patent full text database to be available on STN
 NEWS  15 DEC 30   CAPLUS - PATENT COVERAGE EXPANDED
 NEWS  16 JAN 03   No connect-hour charges in EPFULL during January and
                   February 2005
 NEWS  17 JAN 26   CA/CAPLUS - Expanded patent coverage to include the Russian
                   Agency for Patents and Trademarks (ROSPATENT)

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:37:18 ON 09 FEB 2005

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.84       0.84

FILE 'REGISTRY' ENTERED AT 16:39:37 ON 09 FEB 2005
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4
DICTIONARY FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> fil capl

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.43	1.27

FILE 'CAPLUS' ENTERED AT 16:39:50 ON 09 FEB 2005

FILE COVERS 1907 - 9 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 8 Feb 2005 (20050208/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s pde 4
          4515 PDE
           794 PDES
          4813 PDE
                 (PDE OR PDES)
       5047744 4
L1          210 PDE 4
                 (PDE(W)4)

=> s macular or retinopathy
```

```
          1995 MACULAR
          5929 RETINOPATHY
           181 RETINOPATHIES
          6004 RETINOPATHY
                 (RETINOPATHY OR RETINOPATHIES)
L2        7455 MACULAR OR RETINOPATHY

=> s l1 and l2
L3           2 L1 AND L2

=> d tot

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
Full Text
AN   2004:453020  CAPLUS
DN   141:12309
TI   Compositions comprising (+)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-
     dihydroisoindol-2-yl)propionamide
IN   Muller, George W.; Chen, Roger Shen-chu
PA   Celgene Corporation, USA
SO   PCT Int. Appl., 54 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004045597         A1    20040603    WO 2003-US36740         20031117
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-427379P       P     20021118

L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
Full Text
AN   2003:950880  CAPLUS
DN   140:8834
TI   Topical pharmaceutical compositions containing a PDE 4 inhibitor
IN   Bolle, Christina; Linder, Rudolf
PA   Altana Pharma A.-G., Germany
SO   PCT Int. Appl., 24 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2003099334         A1    20031204    WO 2003-EP5524          20030527
         W:  AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN,
             IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US,
             VN, YU, ZA, ZW
         RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
             DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
```

```
             SI, SK, TR
PRAI DE 2002-10223828     A     20020528
     EP 2002-11830        A     20020528
     DE 2003-10311613     A     20030314
RE.CNT  8     THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s wo2001034606/pn
L4            2 WO2001034606/PN
                (WO2001034606/PN)

=> d

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
Full Text
AN   2003:1001604  CAPLUS
DN   140:42030
TI   Preparation of isoindolinediones as angiogenesis inhibitors.
IN   Man, Hon-wah; Muller, George W.
PA   Celgene Corporation, USA
SO   U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 590,344.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   US 6667316            B1    20031223    US 2000-708199          20001108
     CA 2392081            AA    20010517    CA 2000-2392081         20001109
     WO 2001034606         A1    20010517    WO 2000-US30770         20001109 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1228071            A1    20020807    EP 2000-977095          20001109
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     NZ 519459             A     20031128    NZ 2000-519459          20001109
     JP 2004500346         T2    20040108    JP 2001-536553          20001109
     NO 2002002223         A     20020708    NO 2002-2223            20020508
     FI 2002000892         A     20020510    FI 2002-892             20020510
     US 2004147588         A1    20040729    US 2003-685942          20031014
PRAI US 1999-165168P       P     19991112
     US 2000-590344        A2    20000608
     US 2000-708199        A     20001108
     WO 2000-US30770       W     20001109
OS   MARPAT 140:42030
RE.CNT  65    THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d 2

L4   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text
AN 2001:359998 CAPLUS
DN 134:366799
TI Preparation of isoindolinones for treatment of phosphodiesterase- and TNFα-mediated diseases
IN Man, Hon-Wah; Muller, George
PA Celgene Corporation, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034606	A1	20010517	WO 2000-US30770	20001109 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6667316	B1	20031223	US 2000-708199	20001108
	CA 2392081	AA	20010517	CA 2000-2392081	20001109
	EP 1228071	A1	20020807	EP 2000-977095	20001109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 519459	A	20031128	NZ 2000-519459	20001109
	JP 2004500346	T2	20040108	JP 2001-536553	20001109
	NO 2002002223	A	20020708	NO 2002-2223	20020508
	FI 2002000892	A	20020510	FI 2002-892	20020510
PRAI	US 1999-165168P	P	19991112		
	US 2000-590344	A	20000608		
	US 2000-708199	A	20001108		
	WO 2000-US30770	W	20001109		

OS MARPAT 134:366799
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.10	17.37

FILE 'REGISTRY' ENTERED AT 16:43:41 ON 09 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4
DICTIONARY FILE UPDATES: 8 FEB 2005 HIGHEST RN 827572-71-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> s v-11294A
        208119 V
             1 11294A
L5           1 V-11294A
                 (V(W)11294A)

=> d

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   162278-09-3  REGISTRY
CN   3H-Purin-6-amine, 3-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-N-ethyl-8-
     (1-methylethyl)-, monohydrochloride (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   V 11294A
DR   328248-66-4
MF   C23 H31 N5 O2 . Cl H
SR   CA
LC   STN Files:   BIOSIS, CA, CAPLUS, CASREACT, EMBASE, PROUSDDR, SYNTHLINE,
       TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); USES (Uses)
CRN  (162278-10-6)
```



\# HCl

```
     25 REFERENCES IN FILE CA (1907 TO DATE)
     25 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> s d-4418
       6889239 D
          1081 4418
L6           1 D-4418
                 (D(W)4418)

=> d

L6   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   257892-34-5  REGISTRY
CN   5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy- (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   D 4418
FS   3D CONCORD
DR   199871-60-8
MF   C16 H11 Cl2 N3 O2
SR   CA
LC   STN Files:   BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); MSC (Miscellaneous); PREP
       (Preparation); USES (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); USES (Uses)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             16 REFERENCES IN FILE CA (1907 TO DATE)
             16 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s brl-61063
           385 BRL
             4 BRLS
           389 BRL
                 (BRL OR BRLS)
            31 61063
L7           1 BRL-61063
                 (BRL(W)61063)

=> d
```

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 132210-43-6 REGISTRY
CN 1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 8-Amino-1,3-bis(cyclopropylmethyl)xanthine
CN **BRL 61063**
CN Cipamfylline
FS 3D CONCORD
MF C13 H17 N5 O2
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, DDFU, DRUGU, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL
Other Sources: WHO
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); PRP (Properties); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

44 REFERENCES IN FILE CA (1907 TO DATE)
44 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s sb-207499
         37906 SB
            35 SBS
         37938 SB
                  (SB OR SBS)
             8 207499
L8           1 SB-207499
                  (SB(W)207499)

=> d

L8   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   153259-65-5  REGISTRY
CN   Cyclohexanecarboxylic acid, 4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-
     , cis- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Ariflo
```

CN Cilomilast
CN cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid
CN cis-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4-cyanocyclohexane-1-carboxylic acid
CN **SB 207499**
FS STEREOSEARCH
MF C20 H25 N O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

140 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
142 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel rn name l5
E1 THROUGH E2 ASSIGNED

=> sel rn name l6
E3 THROUGH E4 ASSIGNED

=> sel rn name l7
E5 THROUGH E8 ASSIGNED

=> sel rn name l8
E9 THROUGH E14 ASSIGNED

```
=> fil medl hcapl biosis uspatf wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    47.01      64.38

FILE 'MEDLINE' ENTERED AT 16:45:25 ON 09 FEB 2005

FILE 'HCAPLUS' ENTERED AT 16:45:25 ON 09 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:45:25 ON 09 FEB 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'USPATFULL' ENTERED AT 16:45:25 ON 09 FEB 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:45:25 ON 09 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s e1-2; s e3-4; s e5-8; s e9-14
L9          125 ("V 11294A"/BI OR 162278-09-3/BI)


L10         106 ("D 4418"/BI OR 257892-34-5/BI)


   4 FILES SEARCHED...
L11         182 ("BRL 61063"/BI OR CIPAMFYLLINE/BI OR 132210-43-6/BI OR "8-AMINO
                -1,3-BIS(CYCLOPROPYLMETHYL)XANTHINE"/BI)


   2 FILES SEARCHED...
   4 FILES SEARCHED...
L12         603 (ARIFLO/BI OR CILOMILAST/BI OR "CIS-4-(3-(CYCLOPENTYLOXY)-4-METH
                OXYPHENYL)-4-CYANOCYCLOHEXANE-1-CARBOXYLIC ACID"/BI OR "CIS-4-CY
                ANO-4-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL)CYCLOHEXANECARBOXYLIC
                ACID"/BI OR "SB 207499"/BI OR 153259-65-5/BI)

=> s macular degenerat? or retinopathy
L13       72967 MACULAR DEGENERAT? OR RETINOPATHY

=> s l12 and l13
L14          24 L12 AND L13

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15          24 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib abs 20-24

L15  ANSWER 20 OF 24  WPIDS  COPYRIGHT 2005 THE THOMSON CORP on STN
Full Text
ACCESSION NUMBER:     2004-594021 [57]   WPIDS
DOC. NO. CPI:         C2004-216075
TITLE:                Use of phosphodiesterase-IV along with tumor necrosis
                      factor-alpha for treatment/prophylaxis of e.g. pulmonary
                      inflammatory disorders, pulmonary hypertension and
                      asthma.
```

DERWENT CLASS: B02 B03
INVENTOR(S): WARNER, J M
PATENT ASSIGNEE(S): (PHAA) PHARMACIA CORP
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004067006	A1	20040812	(200457)*	EN	66

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004067006	A1	WO 2004-IB616	20040123

PRIORITY APPLN. INFO: US 2003-442881P 20030127
AN 2004-594021 [57] WPIDS
AB WO2004067006 A UPAB: 20040907
NOVELTY - Treatment or prophylaxis of a phosphodiesterase-IV (PDE-IV) or a tumor necrosis factor- alpha (TNF- alpha) related condition comprises administration of a PDE IV inhibitor (A) together with a TNF- alpha antagonist (B).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for (1) a composition comprising (A) and a TNF-alpha antagonist (B) and a pharmaceutically acceptable excipient; and

(2) a kit for the treatment or prophylaxis of a PDE IV or a TNF-alpha related condition comprising a dosage form comprising (A) and a dosage form comprising (B).

ACTIVITY - Antiinflammatory; Respiratory-Gen.; Hypotensive; Antiasthmatic; Antiallergic; Antiarthritic; Osteopathic; Ophthalmological; Antidiabetic; Antiangiogenic; Antirheumatic; Neuroprotective.

MECHANISM OF ACTION - Phosphodiesterase-IV (PDE IV) inhibitor; TNF-alpha antagonist. Test details are described for TNF- alpha antagonistic activity but no results given.

USE - (A) along with (B) is useful in the treatment of PDE-IV or TNF-alpha related conditions (claimed) such as inflammatory disorders e.g. pulmonary inflammatory disorders, pulmonary hypertension, asthma, exercise induced asthma, pollution induced asthma, allergy induced asthma, chronic obstructive pulmonary disorder (COPD), osteoarthritis, adult respiratory distress syndrome, infant respiratory distress syndrome, retinitis, uveitis, glaucoma, **retinopathy**, diabetic angiopathy, edema formation, arthritis, rheumatoid arthritis and multiple sclerosis.
Dwg.0/0

L15 ANSWER 21 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2003:306096 USPATFULL
TITLE: Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
INVENTOR(S): Graham, Charles H., Kingston, CANADA
Postovit, Lynne-Marie, Kingston, CANADA

Adams, Michael A., Kingston, CANADA
Heaton, Jeremy P.W., Gananoque, CANADA
PATENT ASSIGNEE(S): Queens University at Kingston, Kingston, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215528	A1	20031120
APPLICATION INFO.:	US 2003-384499	A1	20030306 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-42039, filed on 25 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-842547, filed on 26 Apr 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362620P	20020307 (60)
	US 2002-362969P	20020306 (60)
	US 2001-277469P	20010321 (60)
	US 2000-199757P	20000426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 5245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 22 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2003:226433 USPATFULL
TITLE: Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
INVENTOR(S): Berthelette, Carl, Ste-Dorothee Laval, CANADA
Lachance, Nicolas, Pierrefonds, CANADA
Li, Lianhai, Pierrefonds, CANADA
Sturino, Claudio, Beaconsfield, CANADA
Wang, Zhaoyin, Kirkland, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158246	A1	20030821
APPLICATION INFO.:	US 2003-348403	A1	20030121 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-351384P	20020124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 23 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2002:152673 USPATFULL
TITLE: Cyclopentanoindoles, compositions containing such compounds and methods of treatment
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States
Sturino, Claudio, Dorval, CANADA
Roy, Bruno, Ile Bizard, CANADA
Berthelette, Carl, Ste-Dorothee Laval, CANADA
Boyd, Michael, Montreal, CANADA
Lachance, Nicolas, Pierrefonds, CANADA
Scheigetz, John, Dollard des Ormeaux, CANADA
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Yang, Mollie M., Rose, David L.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 24 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2001:235276 USPATFULL
TITLE: Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
INVENTOR(S): Schudt, Christian, Constance, Germany, Federal Republic of
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 6333354	B1	20011225
	WO 9837894		19980903
APPLICATION INFO.:	US 1999-367850		19990827 (9)
	WO 1998-EP1047		19980224
			19990827 PCT 371 date
			19990827 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19708049	19970228

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Krass, Frederick
ASSISTANT EXAMINER: Jagoe, Donna
LEGAL REPRESENTATIVE: Jacobson Holman, PLLC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 24

L15 ANSWER 24 OF 24 USPATFULL on STN

DETD . . . DH-6471, SKF-94120, MOTAPIZONE, LIXAZINONE, INDOLIDAN, OLPRINONE, ATIZORAM, KS-506-G, DIPAMFYLLINE, BMY-43351, ATIZORAM, AROFYLLINE, FILAMINAST, PDB-093, UCB-29646, CDP-840, SKF-107806, PICLAMILAST, RS-17597, RS-25344-000, **SB-207499**, TIBENELAST, SB-210667, SB-211572, SB-211600, SB-212066, SB-212179 and GW-3600, CDP-840, in particular MOPIDAMOL, ANAGRELIDE, IBUDILAST, AMRINONE, PIMOBENDAN, CILOSTAZOL, QUAZINONE and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy4-difluoromethoxybenzamide.

DETD . . . by the combination according to the invention and the obstructions known as "irreversible" in vessel and bronchi can be reduced), **retinopathy**, nephropathy, diabetic angiopathy, edema formation and inflammations (the transpulmonary lymphocyte kinetics and the granulocyte influx) can be effectively prevented.

=> d ibib abs 16-19

L15 ANSWER 16 OF 24 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2004:70711 USPATFULL
TITLE: PDE IV inhibitors to treat angiogenesis
INVENTOR(S): Gamache, Daniel A., Arlington, TX, UNITED STATES
Bingaman, David P., Fort Worth, TX, UNITED STATES
Kapin, Michael A., Arlington, TX, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2004053939 A1 20040318
APPLICATION INFO.: US 2003-660152 A1 20030911 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-411001P	20020916 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Teresa J. Schultz, 6201 South Freeway, Mail Code Q-148, Fort Worth, TX, 76134-2099
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Selective PDE-IV inhibitors are useful for preventing and treating angiogenic/edema related diseases and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 17 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2004:31859 USPATFULL
TITLE: Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
INVENTOR(S): Pitts, William J., Newtown, PA, UNITED STATES
Kim, Soong-Hoon, Titusville, NJ, UNITED STATES
Barbosa, Joseph, Lambertville, NJ, UNITED STATES
Vaccaro, Wayne, Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004024001	A1	20040205
APPLICATION INFO.:	US 2003-423788	A1	20030425 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-375336P	20020425 (60)
	US 2002-428355P	20021122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound having the formula (I), ##STR1##

wherein A, B and D are O or S; R1a and R1b are H, C1-4alkyl, C2-4alkenyl, or C2-4alkynyl; X is --NR2--, --S--, --S(.dbd.O)--, or --S(O)2--; G1, G2 and G3 are together or separately selected from hetero, carbonyl, alkylene, and alkenylene groups and G4 is optionally substituted methylene; R2 is Q-Ar, wherein Q is a linker and Ar is substituted or substituted aryl or heteroaryl; and z is 0 or 1, are useful as inhibitors of MMPs, particularly MMP-13, aggrecanase, and/or TACE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 18 OF 24 USPATFULL on STN

Full Text
ACCESSION NUMBER: 2004:19478 USPATFULL
TITLE: Combination therapy for the treatment of diseases involving inflammatory components
INVENTOR(S): Krause, James E., Madison, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014782	A1	20040122
APPLICATION INFO.:	US 2003-401113	A1	20030327 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-368925P	20020329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leslie-Anne Horvath, Neurogen Corporation, Patent Department, 35 NE Industrial Road, Branford, CT, 06405
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 9573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for treating diseases that are associated with inflammation are provided. Such diseases include arthritis (particularly rheumatoid arthritis) and other autoimmune disorders, asthma, cardio- and cerebrovascular disease, burns, psoriasis, reperfusion injury, and traumatic CNS and spinal cord injury. The compositions generally comprise at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent. The methods involve co-administration of at least one C5a antagonist and at least one C5a receptor-inactive therapeutic agent to a patient. The C5a antagonist and C5a receptor-inactive therapeutic agent may be present within the same composition, or may be administered separately to the patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 19 OF 24 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2004:4504 USPATFULL
TITLE: Tumor necrosis factor receptor 2
INVENTOR(S): Stanton, Jr., Vincent P., Belmont, MA, United States
PATENT ASSIGNEE(S): Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673908	B1	20040106
APPLICATION INFO.:	US 2001-968455		20011001 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-649035, filed on 25 Aug 2000 Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on 1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US 2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252, filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of

Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on 9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US 1999-300747, filed on 26 Apr 1999, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131334P	19990426 (60)
	US 1999-131191P	19990426 (60)
	US 1999-121047P	19990222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Benzion, Gary
ASSISTANT EXAMINER: Chakrabarti, Arun Kr.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 17463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 19

L15 ANSWER 19 OF 24 USPATFULL on STN
SUMM . . . and the following is a list of the progressive complications that are associated with the unregulated carbohydrate balance in tissues: **retinopathy** leading to blindness, nephropathy (diabetic nephropathy is the leading cause of end-stage renal disease), coronary and cardiovascular disease, neuropathy (severe. . .
DETD . . . (methylene)]tetrakis[phos
EDTMP; samarium phonato]](8-)-
EDTMP; CYT 424; N,N',OP,OP', OP",OP'"]-
QUADRAMET samarate(5-)-153Sm
AE 941; NEOVASTAT; unspecified angiogenesis inhibitor; cancer; psoriasis;
NEORETNA; NSAID rheumatoid arthritis;
PSOVASCAR; eye disease;
ARTHROVAS **retinopathy**
FR 111142; WF 2015A 4,5-dihydroxy-2- angiogenesis inhibitor; cancer; rheumatoid
hexenoic acid 5- NSAID arthritis; **retinopathy**
methoxy-4-[2-methyl-3-
(3-methyl-2-
butenyl)oxiranyl]-1-
oxaspiro[2.5]oct-6-yl
ester
troponin I; cartilage unspecified angiogenesis inhibitor; cancer; rheumatoid
derived inhibitor NSAID; arthritis; eye disease
biotechnology
MHC II peptidomimetic,. . . radical scavenging unspecified estrogen; free

radical osteoporosis; arthritis;
estrogens, Jenapharm scavenger; NSAID neurological
TBC 2573 unspecified FGF antagonist; NSAID restenosis; rheumatoid
arthritis; **retinopathy**
CGP 39565 unspecified free radical scavenger; rheumatoid arthritis;
DMARD; NSAID arthritis
superoxide dismutase unspecified free radical scavenger; ischemia; arthritis
B, manganese complex, NSAID
Mn-SOD-B
free. . .
DETD . . . 1228 phosphoric acid phospholipase inhibitor; rheumatoid
arthritis
mono[2- NSAID
[(decylsulfonyl)amino]
octyl)mono[2-
(phenylmethoxy)ethyl]
ester
verteporfin; trans-18-ethenyl-4,4a- photosensitizer; NSAID cancer; psoriasis;
benzoporphyrin dihydro-3,4- arthritis; **retinopathy**
derivative; BPD-MA; CL bis(methoxycarbonyl)-
318952; BPDR; 4a,8,14,19-tetramethyl-
VISUDYNE 23H,25H-
benzo[b]porphine-9,13-
dipropanoic acid
monomethyl ester
polyclonal antibody, unspecified polyclonal antibody; rheumatoid arthritis;
tumor necrosis factor immunoglobulin;. . .
DETD . . . inhibitor; phospho-
diesterase IV inhibitor;
bronchodilator
piclamilast; RP 73401; 3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-
phosphodiesterase asthma; arthritis
RPR 73401 4-methoxybenzamide inhibitor; phospho-
diesterase IV inhibitor;
bronchodilator; NSAID
SB 207499; ARIFLO cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxy-
phosphodiesterase asthma; pulmonary
phenyl]cyclohexanecarboxylic acid inhibitor; phospho- obstructive disease
diesterase IV inhibitor;
bronchodilator; NSAID
D 4418 N-(3,5-dichloro-4-pyridinyl)-8-methoxy-5- phosphodiesterase asthma
quinolinecarboxamide. . .
DETD . . . lipoxygenase inhibitor; inflammation; psoriasis
6,8,9,10- NSAID
tetrahydrobenzo[b][1,8]
naphthyridin-5(7H)-one
AE 941; NEOVASTAT; unspecified angiogenesis inhibitor; cancer; psoriasis;
NEORETNA; NSAID rheumatoid arthritis; eye
PSOVASCAR; disease; **retinopathy**
ARTHROVAS
glycopine; N2-[N-[N-acetyl-4-O-[2- antibiotic; vaccine psoriasis; cancer;
glucosaminylmuramyl (acetylamino)-2-deoxy- adjuvant; leukopenia; septic
dipeptide; GMDP; beta-D- immunostimulant; shock; infectious
LICOPID; LIKOPID glucopyranosyl]muramoyl]- glycopeptide disease; eye disease
. . . emphysema;
proteinase inhibitor psoriasis
efomycines unspecified Endothelium mediated psoriasis
antiadhesive properties
psoriasis enzyme unspecified enzyme psoriasis
therapy

fibroblast growth factor unspecified FGF antagonist; cancer; **retinopathy**;
antagonist angiogenesis inhibitor psoriasis
free radical scavengers unspecified free radical scavenger; neurodegeneration;
NSAID arthritis; reperfusion
injury; psoriasis; stroke
SLH 301 unspecified free radical. . . unspecified photosensitizer;
psoriasis; skin disease;
photodynamic therapy; contrast medium endometriosis; cancer;
5-ALA PDT; LEVULAN diagnosis
verteporfin; trans-18-ethenyl-4,4a- photosensitizer; NSAID cancer; psoriasis;
benzoporphyrin dihydro-3,4- arthritis; **retinopathy**
derivative; BPD-MA; CL bis(methoxycarbonyl)-
318952; BPDR; 4a,8,14,19-tetramethyl-
VISUDYNE 23H,25H-
benzo[b]porphine-9,13-
dipropanoic acid
monomethyl ester
diethylhomospermine; N,N'-bis[4- polyamine analogue diarrhea; hypertension;
DEHOP; DE 444 (ethylamino)butyl]-1,4- cancer;. . .
DETD . . . antagonist psoriasis; cancer
ALRT 1109 unspecified retinoid antagonist; psoriasis
RAR antagonist
lanreotide; BIM 23014; 3-(2-naphthalenyl)-D- somatostatin analogue cancer;
acromegaly;
DC 13116; BIM alanyl-L-cysteinyl-L- **retinopathy**; diabetes;
23014C; BN 52030; tyrosyl-D-tryptophyl-L- psoriasis; restenosis
SOMATULINE; lysyl-L-valyl-L-cysteinyl-
ANGIOPEPTIN; L-threoninamide cyclic
DERMOPEPTIN; (2,7)-disulfide
IPSTYL
octreotide; octreotide [R-(R*,R*)]-D- somatostatin analogue; Alzheimer disease;
acetate; SMS; SMS phenylalanyl-L- analgesic. . .
DETD . . . (E)-O- phosphodiesterase IV
(aminocarbonyl)oxime inhibitor; bronchodilator
piclamilast; RP 73401; 3-cyclopentyloxy-N-(3,5- phosphodiesterase asthma;
arthritis
RPR 73401 dichloropyridin-4-yl)-4- inhibitor;
methoxybenzamide phosphodiesterase IV
inhibitor; bronchodilator
NSAID
SB 207499; **ARIFLO** cis-4-cyano-4-[3- phosphodiesterase asthma; pulmonary
(cyclopentyloxy)-4- inhibitor; obstructive disease
methoxyphenyl]cyclo- phosphodiesterase IV
hexanecarboxylic acid inhibitor; bronchodilator
NSAID
D 4418 Unspecified phosphodiesterase asthma
. . .

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.32	107.70

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:51:28 ON 09 FEB 2005

* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'MEDLINE, HCAPLUS, BIOSIS, USPATFULL, WPIDS'
AT 16:52:44 ON 09 FEB 2005

```
FILE 'MEDLINE' ENTERED AT 16:52:44 ON 09 FEB 2005
FILE 'HCAPLUS' ENTERED AT 16:52:44 ON 09 FEB 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 16:52:44 ON 09 FEB 2005
Copyright (c) 2005 The Thomson Corporation.
FILE 'USPATFULL' ENTERED AT 16:52:44 ON 09 FEB 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'WPIDS' ENTERED AT 16:52:44 ON 09 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      43.32     107.70

=> d his

     (FILE 'HOME' ENTERED AT 16:37:18 ON 09 FEB 2005)

     FILE 'REGISTRY' ENTERED AT 16:39:37 ON 09 FEB 2005

     FILE 'CAPLUS' ENTERED AT 16:39:50 ON 09 FEB 2005
L1           210 S PDE 4
L2          7455 S MACULAR OR RETINOPATHY
L3             2 S L1 AND L2
L4             2 S WO2001034606/PN

     FILE 'REGISTRY' ENTERED AT 16:43:41 ON 09 FEB 2005
L5             1 S V-11294A
L6             1 S D-4418
L7             1 S BRL-61063
L8             1 S SB-207499
                 SEL RN NAME L5
                 SEL RN NAME L6
                 SEL RN NAME L7
                 SEL RN NAME L8

     FILE 'MEDLINE, HCAPLUS, BIOSIS, USPATFULL, WPIDS' ENTERED AT 16:45:25 ON
     09 FEB 2005
L9           125 S E1-2
L10          106 S E3-4
L11          182 S E5-8
L12          603 S E9-14
L13        72967 S MACULAR DEGENERAT? OR RETINOPATHY
L14           24 S L12 AND L13
L15           24 DUP REM L14 (0 DUPLICATES REMOVED)

=> s angiogen?
L16      106020 ANGIOGEN?

=> s angiogenesis or angiogenic
L17      104600 ANGIOGENESIS OR ANGIOGENIC

=> s l17 and l12
L18           33 L17 AND L12

=> dup rem l18
PROCESSING COMPLETED FOR L18
L19           33 DUP REM L18 (0 DUPLICATES REMOVED)

=> d ibib abs 30-33
```

L19 ANSWER 30 OF 33 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2003:134643 USPATFULL
TITLE: Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
INVENTOR(S): Yu, Guixue, Lawrenceville, NJ, UNITED STATES
Macor, John, Guilford, CT, UNITED STATES
Herpin, Timothy, Princeton, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Morton, George C., Collegeville, PA, UNITED STATES
Ruel, Rejean, Saint-Lambert, CANADA
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES
Ruediger, Edward H., Greenfield Park, CANADA
Thibault, Carl, Mascouche, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092732	A1	20030515
APPLICATION INFO.:	US 2002-90582	A1	20020304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 2878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, ##STR1##

in which E is

X is N or CH, W is --NR16R17, --NR16C(.dbd.O)R22, --NR16CO2R22, --OR23, or a heteroaryl or heterocyclo group as defined in the specification, and R1 through R12, R16, R17, R22, R23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 31 OF 33 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2003:100059 USPATFULL
TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
INVENTOR(S): Macor, John E., Guilford, CT, UNITED STATES
Carlson, Kenneth E., West Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069169	A1	20030410

APPLICATION INFO.: US 2002-90258 A1 20020304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-273206P	20010302 (60)
	US 2001-273291P	20010302 (60)
	US 2001-289719P	20010509 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 32 OF 33 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2002:254380 USPATFULL
TITLE: Substituted γ-phenyl-Δ-lactones and analogs thereof and uses related thereto
INVENTOR(S): Shen, Yaping, Port Coquitlam, CANADA
Burgoyne, David L., Delta, CANADA
Lauener, Ronald W., Westminister, CANADA
Zhou, Yuanlin, Richmond, CANADA
Rebstein, Patrick J., Vancouver, CANADA
Abraham, Samuel D. M., Vancouver, CANADA
PATENT ASSIGNEE(S): Inflazyme Pharmaceuticals Ltd., Richmond, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6458829	B1	20021001	
	WO 2000014083		20000316	
APPLICATION INFO.:	US 2001-786949		20010511	(9)
	WO 1999-CA819		19990909	
			20010511	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-149517P	19990817 (60)
	US 1999-121507P	19990223 (60)
	US 1998-99637P	19980909 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Owens, Amelia

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB γ-Phenyl-substituted Δ-lactones and analogs thereof, including lactams, are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 33 OF 33 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2002:152673 USPATFULL
TITLE: Cyclopentanoindoles, compositions containing such compounds and methods of treatment
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States
Sturino, Claudio, Dorval, CANADA
Roy, Bruno, Ile Bizard, CANADA
Berthelette, Carl, Ste-Dorothee Laval, CANADA
Boyd, Michael, Montreal, CANADA
Lachance, Nicolas, Pierrefonds, CANADA
Scheigetz, John, Dollard des Ormeaux, CANADA
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Yang, Mollie M., Rose, David L.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l17 and l11
L20 30 L17 AND L11

=> s 19-12
L21 782 (L9 OR L10 OR L11 OR L12)

=> s l17 and l21
L22 63 L17 AND L21

```
=> s l13 and l21
L23         32 L13 AND L21

=> dup rem l23
PROCESSING COMPLETED FOR L23
L24          32 DUP REM L23 (0 DUPLICATES REMOVED)

=> d ibib abs 29-32

L24  ANSWER 29 OF 32  USPATFULL on STN
Full Text
ACCESSION NUMBER:        2003:207932  USPATFULL
TITLE:                   N-alkyl-adamantyl triazinyl benzamide derivatives
INVENTOR(S):             Duplantier, Allen J., Ledyard, CT, UNITED STATES
PATENT ASSIGNEE(S):      Pfizer Inc. (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003144293      A1   20030731
APPLICATION INFO.:       US 2002-292886     A1   20021112  (10)

                              NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-336892P    20011112 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49,
                         NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS:        23
EXEMPLARY CLAIM:         1
LINE COUNT:              2342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention relates to novel to N-alkyl adamantyl triazinyl
        benzylamide derivatives of formmula I   ##STR1##

        and to processs for their preparation, intermediates useful in their
        preparation, pharmaceutical compositions containing them, and their use
        in therapy. The active compounds of the present invention are useful in
        the treatment of inflammation, osteoarthritis, rhematoid arthritis,
        cancer, reperfusion or ischemia in stroke or heart attack, autoimmune
        diseases and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24  ANSWER 30 OF 32  USPATFULL on STN
Full Text
ACCESSION NUMBER:        2002:288136  USPATFULL
TITLE:                   1,4-dihydropyridine compounds as bradykinin antagonists
INVENTOR(S):             Kawamura, Mitsuhiro, UNITED STATES
                         Kawai, Makoto, UNITED STATES
                         Shishido, Yuji, UNITED STATES
                         Kato, Tomoki, UNITED STATES
                         Katsu, Yasuhiro, UNITED STATES
                         Ikeda, Takafumi, UNITED STATES
                         Murase, Noriaki, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002161006      A1   20021031
```

	US 6653313	B2	20031125
APPLICATION INFO.:	US 2001-903157	A1	20010711 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-224558P	20000810 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 4634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula ##STR1##

wherein each A is independently halo; Y is --(CH2)m--, --C(O)-- or --S(O)--; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 is phenyl substituted at the 2-position with a substituent selected from substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 is hydrogen or C1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 31 OF 32 USPATFULL on STN
Full Text
ACCESSION NUMBER: 2002:152673 USPATFULL
TITLE: Cyclopentanoindoles, compositions containing such compounds and methods of treatment
INVENTOR(S): Labelle, Marc, Burlingame, CA, United States
Sturino, Claudio, Dorval, CANADA
Roy, Bruno, Ile Bizard, CANADA
Berthelette, Carl, Ste-Dorothee Laval, CANADA
Boyd, Michael, Montreal, CANADA
Lachance, Nicolas, Pierrefonds, CANADA
Scheigetz, John, Dollard des Ormeaux, CANADA
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Kirkland, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410583	B1	20020625
APPLICATION INFO.:	US 2001-909636		20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-220683P	20000725 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Yang, Mollie M., Rose, David L.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1802

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted cyclopentanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 32 OF 32 USPATFULL on STN

Full Text

ACCESSION NUMBER: 2001:235276 USPATFULL

TITLE: Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists

INVENTOR(S): Schudt, Christian, Constance, Germany, Federal Republic of

PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik GmbH, Constance, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6333354	B1	20011225	
	WO 9837894		19980903	
APPLICATION INFO.:	US 1999-367850		19990827	(9)
	WO 1998-EP1047		19980224	
			19990827	PCT 371 date
			19990827	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19708049	19970228

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Krass, Frederick

ASSISTANT EXAMINER: Jagoe, Donna

LEGAL REPRESENTATIVE: Jacobson Holman, PLLC

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1

LINE COUNT: 255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	98.05	162.43

FILE 'STNGUIDE' ENTERED AT 17:05:21 ON 09 FEB 2005

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 4, 2005 (20050204/UP).

STN Columbus

=>